We are developing a pipeline of potentially best-in-class therapies aimed at transforming the standard of care for patients living with autoimmune diseases. Our programs build on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Jade’s lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug-enabling studies underway and first-in-human trials expected to initiate in the second half of 2025.